The effect of nephrectomy on Klotho, FGF-23 and bone metabolism

被引:9
|
作者
Kakareko, Katarzyna [1 ]
Rydzewska-Rosolowska, Alicja [1 ]
Brzosko, Szymon [1 ]
Gozdzikiewicz-Lapinska, Joanna [2 ]
Koc-Zorawska, Ewa [2 ]
Samocik, Pawel [3 ]
Kozlowski, Robert [3 ]
Mysliwiec, Michal [1 ]
Naumnik, Beata [1 ]
Hryszko, Tomasz [1 ]
机构
[1] Med Univ Bialystok, Dept Nephrol & Transplantat 1, Dialysis Unit, Ul Zurawia 14, PL-15540 Bialystok, Poland
[2] Med Univ Bialystok, Dept Hypertens & Nephrol 1, Dialysis Unit, Bialystok, Poland
[3] J Sniadecki Prov Hosp, Dept Oncol & Gen Urol, Bialystok, Poland
关键词
Acute GFR decline; Nephrectomy; Klotho; FGF-23; Bone metabolism; GROWTH-FACTOR; 23; ACUTE KIDNEY INJURY; MINERAL METABOLISM; CARDIAC-SURGERY; SERUM-LEVELS; PHOSPHATE; DISEASE; FGF23; CKD; FACTOR-23;
D O I
10.1007/s11255-017-1519-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Increased concentration of fibroblast growth factor 23 (FGF-23) and decreased levels of soluble Klotho (sKL) are linked to negative clinical outcomes among patients with chronic kidney disease and acute kidney injury. Therefore, it is reasonable to hypothesize that GFR reduction caused by nephrectomy might alter mineral metabolism and induces adverse consequences. Whether nephrectomy due to urological indications causes derangements in FGF-23 and sKL has not been studied. The aim of the study was to evaluate the effect of acute GFR decline due to unilateral nephrectomy on bone metabolism, FGF-23 and sKL levels. Methods This is a prospective, single-centre observational study of patients undergoing nephrectomy due to urological indications. Levels of C-terminal FGF-23 (c-FGF-23), sKL and bone turnover markers [beta-crosslaps (CTX), bone-specific alkaline phosphatase (bALP) and tartrate-resistant acid phosphatase 5b (TRAP 5b)] were measured before and after surgery (5 +/- 2 days). Results Twenty-nine patients were studied (14 females, age 63.0 +/- 11.6, eGFR 87.3 +/- 19.2 ml/min/1.73 m(2)). After surgery, eGFR significantly declined (p < 0.0001). Nephrectomy significantly decreased sKL level [709.8 (599.9-831.2) vs. 583.0 (411.7-752.6) pg/ml, p < 0.001] and did not change c-FGF-23 concentration [70.5 (49.8-103.3) vs. 77.1 (60.5-109.1) RU/ml, p = 0.9]. Simultaneously, alterations in bone turnover markers were observed. Serum concentration of CTX increased [0.49 (0.4-0.64) vs. 0.59 (0.46-0.85) ng/ml, p = 0.001], while bALP and TRAP 5b decreased [23.6 (18.8-31.4) vs. 17.9 (15.0-22.0) U/l, p < 0.0001 and 3.3 (3.0-3.7) vs. 2.8 (2.3-3.2) U/l, p < 0.001, respectively]. Conclusions Nephrectomy among patients with preserved renal function before surgery does not increase c-FGF-23 but reduces sKL. Moreover, nephrectomy results in derangements in bone turnover markers in short-term follow-up. These changes may participate in pathogenesis of bone disease after nephrectomy.
引用
收藏
页码:681 / 688
页数:8
相关论文
共 50 条
  • [21] FGF23-klotho axis in CKD
    Takashi Y.
    Fukumoto S.
    Renal Replacement Therapy, 2 (1) : 1 - 5
  • [22] Overview of the FGF23-Klotho axis
    Makoto Kuro-o
    Pediatric Nephrology, 2010, 25 : 583 - 590
  • [23] FGF23/Klotho axis: Phosphorus, mineral metabolism and beyond
    Donate-Correa, Javier
    Muros-de-Fuentes, Mercedes
    Mora-Fernandez, Carmen
    Navarro-Gonzalez, Juan F.
    CYTOKINE & GROWTH FACTOR REVIEWS, 2012, 23 (1-2) : 37 - 46
  • [24] FGF-23 and sclerostin in serum and bone of CKD patients
    Lima, Florence
    Monier-Faugere, Marie-Claude
    Mawad, Hanna
    David, Valentin
    Malluche, Hartmut H.
    CLINICAL NEPHROLOGY, 2023, 99 (05) : 209 - 218
  • [25] Phosphate and FGF-23
    Jueppner, Harald
    KIDNEY INTERNATIONAL, 2011, 79 : S24 - S27
  • [26] Assessment of the Concentration of Bone Metabolism Markers: Sclerostin and FGF-23 in Children with Idiopathic Nephrotic Syndrome Treated with Glucocorticosteroids
    Pukajlo-Marczyk, Agnieszka
    Jakubowska, Anna
    Bargenda-Lange, Agnieszka
    Kilis-Pstrusinska, Katarzyna
    Zwolinska, Danuta
    DISEASE MARKERS, 2019, 2019
  • [27] FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism
    Seiji Fukumoto
    Calcified Tissue International, 2016, 98 : 334 - 340
  • [28] FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study
    Desbiens, L. -C.
    Sidibe, A.
    Ung, R. -V.
    Fortier, C.
    Munger, M.
    Wang, Y. -P.
    Bisson, S. -K.
    Marquis, K.
    Agharazii, M.
    Mac-Way, F.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 (10) : 2345 - 2353
  • [29] Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis
    von Jeinsen, Beatrice
    Sopova, Kateryna
    Palapies, Lars
    Leistner, David M.
    Fichtlscherer, Stephan
    Seeger, Florian H.
    Honold, Joerg
    Dimmeler, Stefanie
    Assmus, Birgit
    Zeiher, Andreas M.
    Keller, Till
    ESC HEART FAILURE, 2019, 6 (03): : 536 - 544
  • [30] Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism
    Tomasz Hryszko
    Szymon Brzosko
    Alicja Rydzewska-Rosolowska
    Ewa Koc-Zorawska
    Michal Mysliwiec
    International Urology and Nephrology, 2012, 44 : 1479 - 1486